BORSA: Stock News & AlertsFree on the App StoreFree on Google PlayGet Get

BORSAStock News & Alerts

Latest News Calendar Reports Stocks Sign in

BORSAStock News & Alerts

Latest News Calendar Reports Stocks Sign in

SPYPrev. session+0.12%$767.50Oct 19, 19:59 ET QQQPrev. session+0.10%$719.05Oct 19, 19:59 ET

SPCXPrev. session+0.51%$148.72Oct 19, 19:59 ET STLDPrev. session−4.64%$233.79Oct 19, 19:59 ET MRDNPrev. session0.00%$11.19Oct 19, 16:10 ET NDAQPrev. session+0.32%$93.50Oct 19, 19:55 ET RLIPrev. session+0.06%$61.20Oct 19, 19:52 ET BABAPrev. session+0.19%$108.75Oct 19, 19:59 ET AMPLPrev. session0.00%$15.18Oct 19, 19:30 ET DDOGPrev. session+0.61%$261.94Oct 19, 19:58 ET EXCPrev. session−0.38%$42.25Oct 19, 19:47 ET CCKPrev. session−3.68%$110.57Oct 19, 19:59 ET AGNCPrev. session−1.30%$8.33Oct 19, 19:59 ET AZNPrev. session+1.59%$166.63Oct 19, 19:41 ET BXPrev. session+0.27%$107.40Oct 19, 19:59 ET MAMAPrev. session0.00%$12.91Oct 19, 19:30 ET BLKPrev. session+0.28%$1,128.00Oct 19, 19:54 ET TBLAPrev. session0.00%$3.45Oct 19, 19:30 ET AVGOPrev. session+0.33%$335.70Oct 19, 19:59 ET HONAPrev. session+0.30%$162.97Oct 19, 19:57 ET TSATPrev. session−0.85%$44.50Oct 19, 19:30 ET DUOLPrev. session+0.63%$143.00Oct 19, 19:59 ET XOMPrev. session−0.03%$178.25Oct 19, 19:59 ET CPrev. session+0.11%$121.84Oct 19, 19:58 ET NFLXPrev. session−0.26%$69.67Oct 19, 19:59 ET KMBPrev. session+0.13%$105.55Oct 19, 19:34 ET VLGEAPrev. session0.00%$43.57Oct 19, 19:30 ET DXPrev. session+0.09%$10.58Oct 19, 19:55 ET CLFPrev. session+0.07%$14.12Oct 19, 19:59 ET ZIONPrev. session+2.15%$64.50Oct 19, 19:53 ET FTKPrev. session−1.14%$24.27Oct 19, 19:30 ET GSPrev. session+0.05%$876.25Oct 19, 19:57 ET SPCXPrev. session+0.51%$148.72Oct 19, 19:59 ET STLDPrev. session−4.64%$233.79Oct 19, 19:59 ET MRDNPrev. session0.00%$11.19Oct 19, 16:10 ET NDAQPrev. session+0.32%$93.50Oct 19, 19:55 ET RLIPrev. session+0.06%$61.20Oct 19, 19:52 ET BABAPrev. session+0.19%$108.75Oct 19, 19:59 ET AMPLPrev. session0.00%$15.18Oct 19, 19:30 ET DDOGPrev. session+0.61%$261.94Oct 19, 19:58 ET EXCPrev. session−0.38%$42.25Oct 19, 19:47 ET CCKPrev. session−3.68%$110.57Oct 19, 19:59 ET AGNCPrev. session−1.30%$8.33Oct 19, 19:59 ET AZNPrev. session+1.59%$166.63Oct 19, 19:41 ET BXPrev. session+0.27%$107.40Oct 19, 19:59 ET MAMAPrev. session0.00%$12.91Oct 19, 19:30 ET BLKPrev. session+0.28%$1,128.00Oct 19, 19:54 ET TBLAPrev. session0.00%$3.45Oct 19, 19:30 ET AVGOPrev. session+0.33%$335.70Oct 19, 19:59 ET HONAPrev. session+0.30%$162.97Oct 19, 19:57 ET TSATPrev. session−0.85%$44.50Oct 19, 19:30 ET DUOLPrev. session+0.63%$143.00Oct 19, 19:59 ET XOMPrev. session−0.03%$178.25Oct 19, 19:59 ET CPrev. session+0.11%$121.84Oct 19, 19:58 ET NFLXPrev. session−0.26%$69.67Oct 19, 19:59 ET KMBPrev. session+0.13%$105.55Oct 19, 19:34 ET VLGEAPrev. session0.00%$43.57Oct 19, 19:30 ET DXPrev. session+0.09%$10.58Oct 19, 19:55 ET CLFPrev. session+0.07%$14.12Oct 19, 19:59 ET ZIONPrev. session+2.15%$64.50Oct 19, 19:53 ET FTKPrev. session−1.14%$24.27Oct 19, 19:30 ET GSPrev. session+0.05%$876.25Oct 19, 19:57 ET

← Novo Nordisk A/S (NVO) stock news

Novo Nordisk A/S (NVO) Stock News: October 2026

$NVO · 4 stories in October 2026

October 2026

newest first · direct subject stories only

CorporateOct 19 · 7:53 AM ET

Novo Nordisk updates share buyback progress with weekly transactions

Novo Nordisk updates share buyback progress with weekly transactions.

neutral 50 · impact 10

Analyst actionOct 19 · 1:22 AM ET

HSBC lowers Novo Nordisk price target to DKK 280

HSBC reduced its price target for Novo Nordisk by DKK 40.

bearish 35 · impact 30

HSBC lowers Novo Nordisk price target, shown as a downward arrow touching a pill bottle.

BORSA News Sentiment is a news-derived editorial measure, separate from price action and not investment advice.

News Calendar Reports Stocks Sign in

CorporateOct 12 · 6:29 AM ET

Novo Nordisk provides weekly update on share buyback programme

Novo Nordisk provides weekly update on share buyback programme.

bullish 60 · impact 20

Novo Nordisk share buyback: a pharmaceutical vial being replenished with a medical token using large tweezers.

CorporateOct 2 · 10:55 PM ET

FDA continues review of Novo Nordisk's denecimig BLA for haemophilia A

The FDA is continuing its review of Novo Nordisk's Biologics License Application for denecimig, a treatment for haemophilia A. No decision has been announced.

neutral 50 · impact 20

Novo Nordisk's denecimig under FDA review: a medical vial on a stone pedestal being examined through a large magnifying glass.

More Novo Nordisk A/S coverage$NVO

Latest NVO stock news · September 2026 · August 2026

BORSA News Sentiment is a news-derived editorial measure, separate from price action and not investment advice.